Loading patent…
AssigneeAgenus Inc.
InventorsNicholas S. WILSON, Jeremy D. Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
Estimating the term…
The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGFβ-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
An isolated polynucleotide encoding a heavy chain variable region or a light chain variable region of an antibody, wherein the heavy chain variable region comprises complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3, and the light chain variable region comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein:
A recombinant host cell comprising a first polynucleotide encoding a heavy chain variable region or a heavy chain of an antibody and a second polynucleotide encoding a light chain variable region or a light chain of the antibody, wherein the antibody comprises:
Dependencies are inferred from the claim text.